Bovax Biotechnology

Focus: Bovax Biotechnology is a China-based biotech company specializing in recombinant protein vaccines, with a focused pipeline in HPV vaccine development across multiple valencies and indications.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Bovax Biotechnology

AI assessmentNot Hiring

No open roles listed right now. Follow Bovax Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

HPV Infections

N/A

Clinical Trials (1)

NCT05371353Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

N/A

Help build intelligence for Bovax Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Heavy pipeline momentum in Phase 3 with 7 active programs, predominantly in high-demand HPV vaccines across multiple indications (cervical cancer, genital warts, penile cancer).
Positioned in infectious diseases and vaccines, a therapeutic area with sustained public health demand and government procurement opportunities in Asia-Pacific markets.
Specialized focus on recombinant protein vaccines offers technical depth for scientists seeking expertise in a differentiated modality with manufacturing scale advantages.

Watch Out For

Zero active job openings and no hiring data visible, indicating either minimal expansion or opaque recruitment—significant uncertainty about career growth trajectory.
Critical company data gaps (founding date, employee count, funding stage, financial health, revenue) suggest limited public transparency typical of early-stage Chinese biotech, raising concerns about institutional maturity and internal resources.
No publications, FDA warning history, or recent news in dataset limits ability to assess scientific rigor, regulatory relationships, or organizational credibility.
Heterogeneous pipeline naming and phase organization (e.g., 'Placebo' as drug name, redundant HPV programs) suggests early clinical development or data quality issues that may reflect operational immaturity.

Generated by Claude from Bovax Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Placebo

HPV Infection

Phase 1

Clinical Trials (1)

NCT06454175A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

Phase 1

Placebo among 18-45 yrs

Penile Cancer

Phase 1

Clinical Trials (1)

NCT05518201Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Phase 1